On September 10, METIS TECHBIO-P fell 5.06% in regular trading, trading at 17.35 HKD/share, with turnover of approximately HKD 88.39 million. The decline came as short-term profit-taking pressure mounted following a sharp rally since the stock's inclusion in the Stock Connect program.

METIS TECHBIO-P was officially added to the Stock Connect eligible securities list on September 7, unlocking access for mainland investors via southbound trading. The inclusion triggered a powerful rally, with the stock surging over 40% cumulatively across just three trading sessions — rising roughly 11% on the first day, then extending gains with an intraday spike exceeding 20% on September 8, fueled by the simultaneous announcement of a strategic AI drug delivery partnership with Luye Pharma.

The rapid accumulation of short-term gains has created significant profit-taking pressure. Adding to the headwinds, the broader biotechnology sector turned notably weak on September 10, with peers including Innovent Bio down 2.75%, Everest Medicines down 8.07%, and 3SBio down 3.16%, reflecting softening sector sentiment that amplified the pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)